It is therefore proposed that the use of epigenomic editors which activate antifibrotic genes, including RASAL1, KL, and IL-10, may represent a promising approach for the treatment of acute kidney injury and fibrosis. This evidence concerns the gene RASAL1 and acute kidney injury.